The Hinf-P/P220 Cell Cycle Signaling Pathway Controls Nonhistone
Total Page:16
File Type:pdf, Size:1020Kb
Research Article The HiNF-P/p220NPAT Cell Cycle Signaling Pathway Controls Nonhistone Target Genes Ricardo Medina, Margaretha van der Deen, Angela Miele-Chamberland, Rong-Lin Xie, Andre J. van Wijnen, Janet L. Stein, and Gary S. Stein Department of Cell Biology and Cancer Center, University of Massachusetts Medical School, Worcester, Massachusetts Abstract Whereas the HiNF-P/p220NPAT pathway plays a key role in HiNF-P and its cofactor p220NPAT are principal factors S-phase entry, the majority of data on cyclin E/CDK2 signaling is regulating histone gene expression at the G -S phase cell centered on the target genes of E2F factors. The E2F proteins had 1 been shown earlier to support S-phase entry and are activated cycle transition. Here,we have investigated whether HiNF-P controls other cell cycle– and cancer-related genes. We used following release from repressive RB-related pocket protein cDNA microarrays to monitor responsiveness of gene expres- complexes through CDK-dependent phosphorylation at the restric- sion to small interfering RNA–mediated depletion of HiNF-P. tion point (10, 11). E2F targets include a number of genes encoding Candidate HiNF-P target genes were examined for the enzymes that are required for nucleotide metabolism as well as presence of HiNF-P recognition motifs, in vitro HiNF-P binding proteins involved in DNA replication and cyclin subunits for CDKs. to DNA,and in vivo association by chromatin immunopreci- The recent realization that cyclin E/CDK2 signaling diverges into pitations and functional reporter gene assays. Of 177 the E2F and HiNF-P pathways (2) necessitates examination of proliferation-related genes we tested,20 are modulated in HiNF-P target genes to gain a more comprehensive understanding HiNF-P–depleted cells and contain putative HiNF-P binding of regulatory events that control the onset of S phase. motifs. We validated that at least three genes (i.e., ATM, To examine the role of HiNF-P in the transcription of nonhistone PRKDC,and CKS2) are HiNF-P dependent and provide data genes, we searched for other genes targeted by HiNF-P in indicating that the DNA damage response is altered in HiNF- asynchronous cells. Here, we have characterized HiNF-P target genes to identify nonhistone cell cycle–related pathways in which P–depleted cells. We conclude that,in addition to histone genes,HiNF-P also regulates expression of nonhistone targets HiNF-P may participate. We have characterized genes that are that influence competency for cell cycle progression. [Cancer modulated in response to HiNF-P small interfering RNA (siRNA) Res 2007;67(21):10334–42] treatment. Genes directly regulated by HiNF-P were defined by in vitro binding assays, reporter gene assays, and chromatin immunoprecipitations that establish binding of HiNF-P to Introduction endogenous chromatin-embedded promoters. One principal result HiNF-P is the gene regulatory end point for the cyclin E/cyclin- of this study is that HiNF-P interacts with divergently transcribed NPAT dependent kinase (CDK)-2/p220 pathway that activates genes encoding proteins that are involved in DNA damage multiple histone H4 genes and supports chromatin packaging of response pathways (e.g., ATM-p220NPAT and PRKDC-MCM4). We nascent DNA (1–7). This pathway may be a key component of a also show that HiNF-P deficiency impairs DNA repair. Based on broader cell cycle checkpoint (‘‘S point’’) defined, in part, by these findings, we suggest that HiNF-P may have important cell HiNF-P–responsive genes that are distinct from those encoding cycle regulatory functions that are complementary to its role in histones. The cell cycle regulatory role of HiNF-P in controlling controlling histone gene expression. histone gene expression is functionally coupled to formation of a HiNF-P/p220NPAT transcriptional coactivation complex (2). Whereas p220NPAT colocalizes with HiNF-P and histone genes at Materials and Methods the G1-S phase transition when transcriptional activation occurs, HiNF-P depletion by siRNA. For siRNA-mediated knockdown of HiNF-P this protein seems to be spatially restricted to two to four large mRNA, human T98G glioblastoma, human HeLa S3 cervical adenocarcino- subnuclear foci (related to Cajal bodies; refs. 2, 4–6). Our ma, or human U-2 OS osteosarcoma cells were transfected in six-well plates immunofluorescence data reveal that a significant fraction of with either siCONTROL Non-Targeting siRNA#1 (Dharmacon), Silencer HiNF-P is also located at a large number of other smaller Negative Control #1 siRNA (Ambion, Inc.), or HiNF-P–specific double- subnuclear foci (2). We have shown that expression of HiNF-P is stranded siRNA oligonucleotides (Ambion, Inc.) with Oligofectamine proliferation related (1, 8, 9). Depletion of HiNF-P decreases histone according to the manufacturer’s instructions (Invitrogen). H4 mRNA levels in asynchronous cells and delays progression into Cell cycle and cancer gene expression arrays. DNA-free total RNA S phase following serum stimulation of quiescent cells (1). These samples isolated from control and HiNF-P siRNA–treated T98G cells were used for probe synthesis in the presence of [a-32P]dCTP according to the data show that HiNF-P is a critical component of the cell cycle– manufacturer’s protocol (SuperArray Bioscience Corp.). This probe was dependent mechanisms that respond to cyclin E/CDK2 to achieve subsequently used to hybridize human cell cycle and cancer GEArray competency for S-phase entry. Q Series cDNA gene arrays following the instructions of the same manu- facturer. Spot intensities were quantified with a Storm 840 PhosphoImager using ImageQuant 5.0 software (Molecular Dynamics) and normalized to Requests for reprints: Gary S. Stein, Department of Cell Biology and Cancer the controls provided in the array. Hierarchical clustering was used to Center, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, analyze the data, and cDNAs with normalized signal intensity values that MA 01655. Phone: 508-856-5625; Fax: 508-856-6800; E-mail: [email protected]. I2007American Association for Cancer Research. differed by at least 1.4-fold between siCONTROL and HiNF-P siRNA doi:10.1158/0008-5472.CAN-07-1560 oligonucleotides were further investigated. Cancer Res 2007; 67: (21). November 1, 2007 10334 www.aacrjournals.org Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 2007 American Association for Cancer Research. Novel Nonhistone HiNF-P Target Genes cDNA synthesis and real-time quantitative PCR. Total RNA from Chromatin immunoprecipitations. T98G cells were washed twice with siCONTROL Non-Targeting siRNA#1 (Dharmacon) and HiNF-P siRNA– ice-cold 1Â PBS and subsequently cross-linked with 1% formaldehyde in treated HeLa cells was either subjected to DNase I digestion and purified by 1Â PBS for 10 min at room temperature with gentle agitation. To quench column chromatography (DNA-free RNA Kit, Zymo Research) or purified the cross-linking reaction, 0.125 M glycine in 1Â PBS was added for 5 min. using the RNeasy Plus Mini Kit (Qiagen) and used to prepare cDNA with the Cells were then washed twice with ice-cold 1Â PBS, scraped in lysis buffer SuperScript First-Strand Synthesis System (Invitrogen). Quantitation was [50 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% NP40, 2Â Complete determined using a 7000 sequence detection system (Applied Biosystems) protease inhibitor] and incubated on ice for 20 min. Lysates were sonicated and SYBR Green chemistry (SYBR Green PCR Master Mix, Applied to an average DNA size of 100 to 500 bp and then cleared by centrifugation Biosystems). The relative mRNA expression was determined by the DDCT at 14,000 rpm for 15 min at 4jC. Crude rabbit antiserum (3 AL) against method. The following primer pairs were used for human mRNAs HiNF-P, pre-bleed serum (3 AL), or 2 Ag of RNA polymerase II antibody were (in 5¶-3¶ direction): HiNF-P forward, GAGGAGGATGACCCACTTGA, and added and rotated at 4jC overnight. One-tenth volume of protein A/G reverse, TCAGCTTGGTGTGGTAGCAG; H4/n forward AGCTGTCTATCG- beads (Santa Cruz Biotechnology) was added for 1 h at 4jC. Beads were GGCTCCAG, and reverse, CCTTTGCCTAAGCCTTTTCC; ATM forward, then washed consecutively with the following buffers: low-salt [20 mmol/L CTGTGGTGGAGGGAAGATGT, and reverse, GTTGATGAGGGGATTGCTGT; Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% Triton X-100, 2 mmol/L EDTA, p220NPAT forward, TCCAGCCTGCTTACTGTCCT, and reverse, AGCAAA- 1Â Complete protease inhibitor], high-salt [20 mmol/L Tris-HCl (pH 8.0), CCTTGGGGAACTTT; PRKDC forward, TGCAGCTGATTCACTGGTTC, and 500 mmol/L NaCl, 1% Triton X-100, 2 mmol/L EDTA], LiCl [10 mmol/L reverse, TCGAATACACCGACCACAAA; MCM4 forward, TGAAGCCATT- Tris-HCl (pH 8.0), 250 mmol/L LiCl, 1% deoxycholate, 1% NP40, 1 mmol/L GATGTGGAAG, and reverse, GGCACTCATCCCCGTAGTAA; CKS2 forward, EDTA], and three washes with Tris-EDTA [10 mmol/L Tris-HCl (pH 8.0), ACCGGCATGTTATGTTACCC, and reverse, TGTGGTTCTGGCTCATGAAT; 1 mmol/L EDTA]. Protein/DNA complexes were eluted twice with elution and RB1 forward, TTCACCCTTACGGATTCCTG, and reverse, AGTCCC- buffer (1% SDS, 100 mmol/L NaHCO3) at room temperature. One-tenth GAATGATTCACCAA. volume of 3 mol/L sodium acetate (pH 5.2) was added and samples were Differences in RNA levels between control and HiNF-P–specific siRNA incubated at 65jC overnight to reverse cross-links. Genomic DNA was oligonucleotides were elevated using general linear mixed models (12). purified by phenol-chloroform extraction followed by isopropanol precip- Models were fit by restricted maximum likelihood estimation (13) using the itation with 5 to 20 Ag of glycogen carrier and dissolved in resuspension SAS Proc Mixed procedure (14). In the presence of significant differences buffer (10 mmol/L Tris-HCl, pH 8.0). among means, pairwise comparisons were made using Fisher’s least Analysis of chromatin immunoprecipitations by real-time quanti- significant difference test using the estimated covariance matrix to account tative PCR.